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Abstract
Objective—Proton magnetic resonance spectroscopy (1H MRS) in opiate dependence showed 
abnormalities in neuronal viability and glutamate concentration in the anterior cingulate cortex 
(ACC). Metabolite levels in dorsolateral prefrontal cortex (DLPFC) or orbitofrontal cortex (OFC) 
and their neuropsychological correlates have not been investigated in opiate dependence.
Methods—Single-volume proton MRS at 4 Tesla and neuropsychological testing were conducted 
in 21 opiate-dependent individuals (OD) on buprenorphine maintenance therapy. Results were 
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compared to 28 controls (CON) and 35 alcohol-dependent individuals (ALC), commonly 
investigated treatment-seekers providing context for OD evaluation. Metabolite concentrations 
were measured from ACC, DLPFC, OFC and parieto-occipital cortical (POC) regions.
Results—Compared to CON, OD had lower concentrations of N-acetylaspartate (NAA), 
glutamate (Glu), creatine +phosphocreatine (Cr) and myo-Inositol (mI) in the DLPFC and lower 
NAA, Cr, and mI in the ACC. OD, ALC, and CON were equivalent on metabolite levels in the 
POC and γ-aminobutyric acid (GABA) concentration did not differ between groups in any region. 
In OD, prefrontal metabolite deficits in ACC Glu as well as DLPFC NAA and choline containing 
metabolites (Cho) correlated with poorer working memory, executive and visuospatial functioning; 
metabolite deficits in DLPFC Glu and ACC GABA and Cr correlated with substance use 
measures. In the OFC of OD, Glu and choline-containing metabolites were elevated and lower Cr 
concentration related to higher nonplanning impulsivity. Compared to 3 week abstinent ALC, OD 
had significant DLPFC metabolite deficits.
Conclusion—The anterior frontal metabolite profile of OD differed significantly from that of 
CON and ALC. The frontal lobe metabolite abnormalities in OD and their neuropsychological 
correlates may play a role in treatment outcome and could be explored as specific targets for 
improved OD treatment.
Keywords
Alcoholism; Brain; Cognition; Opiate; Proton magnetic resonance spectroscopy; Smoking
Introduction
The misuse of opiates is a serious problem worldwide, is increasing in young adults [1–3], 
and has substantial individual and societal consequences. In 2014 in the United States alone, 
approximately 1.9 million people had an opiate use disorder, including 586,000 heroin users 
[2]. Neuroimaging in opiate dependence indicates both altered brain structure, particularly in 
the anterior cingulate cortex (ACC; [4–7]), and brain function involving dorsolateral 
prefrontal cortex (DLPFC) and ACC [8,9]. Magnetic resonance spectroscopy (1H MRS) 
allows the non-invasive quantitation of brain metabolites that provide information on the 
neurophysiologic integrity of brain tissue [10]. The few 1H MRS studies in opiate 
dependence to date revealed lower concentration of N-acetylaspartate (NAA), a marker of 
neuronal integrity, in the medial frontal cortex, including the ACC [11–13], as well as lower 
glutamate (Glu), a primary excitatory neurotransmitter, or glutamate+glutamine 
concentration in some [11,13,14] but not all studies [15]. The discrepant MRS findings may 
relate to differences among study participants regarding the prevalence and severity of 
comorbid substance use (i.e., alcohol, tobacco, illicit drugs), the type, dose and duration of 
replacement therapy for heroin users (buprenorphine, methadone), and/or participant age.
The ACC, DLPFC and orbitofrontal cortex (OFC) are important components of the brain 
reward/executive oversight system, a neural network critically involved in the development 
and maintenance of addictive disorders [16,17]. Structural brain imaging in opiate 
dependence revealed generally lower gray matter volume or density in (pre)frontal regions 
[5–7,9,18], including the DLPFC [9,19], with thinner frontal cortices related to longer 
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duration of opiate misuse [4]. Functional MR imaging showed that the DLPFC, OFC and 
ACC are involved in decision making [20–22], and in opiate dependent individuals, lower 
task-based fMRI activity in the ACC [8] related to compromised behavioural control of 
cognitive interference [8,11]. Furthermore, smaller frontal gray matter volume in opiate 
dependence related to higher impulsivity on the Barratt Impulsivity Scale (BIS-11; [19,23]). 
Correspondingly, opiate dependence is associated with cognitive deficits [24–28], primarily 
in executive functioning and self-regulation (impulsivity, decision-making, risk taking 
[19,29]). Thus, the neuroimaging literature in opiate dependence suggests altered frontal 
brain structure as well as compromised neuronal integrity and glutamatergic metabolism. 
Few if any studies however investigated their relationships to opioid and other substance use 
behaviour or cognition. Further research into specific regional brain effects and their 
potential cognitive and behavioural correlates may inform better targeted treatment of 
individuals with opioid use disorders.
We measured in opiate dependent individuals’ metabolite concentrations from the ACC and 
previously unexplored DLPFC and OFC and related them to quantitative measures of 
neurocognition, self-regulation, and substance use. Specifically, we compared opiate 
dependent individuals (OD) on buprenorphine maintenance to controls (CON). We also 
included another control group, a substance-dependent ‘control’ group of 3 week abstinent 
alcohol dependent individuals (ALC), a commonly investigated treatment-seeking group to 
differentiate opiate dependence from not only control individuals but also individuals with a 
substance dependence (here, alcohol dependence). Our primary hypotheses were that: (1) 
OD have lower NAA and Glu concentrations than CON in ACC, DLPFC, and OFC, (2) 
these frontal cortical NAA and Glu deficits are associated with the level of opiate use and 
cigarette-smoking severity, (3) the frontal NAA and Glu deficits in OD relate to higher 
impulsivity, poorer executive function, and lower decision making skills, and (4) OD have 
more pronounced metabolite concentration deficits than ALC. The results of this study will 
contribute to a better understanding of the neurobiology and neuropsychology in OD, 
helping to identify novel targets for the treatment of opiate dependence.
Materials and Method
Participant characterization
All participants provided informed consent according to the Declaration of Helsinki and 
underwent procedures approved by the University of California, San Francisco and San 
Francisco VA Medical Center (Federalwide Assurance (FWA) 00000068). Twenty-one 
chronic cigarette smoking OD, stable on buprenorphine maintenance therapy for at least 3 
months, met DSM-IV criteria for dependence on opiates; they were allowed to meet DSM-
IV criteria for current abuse or dependence on cocaine, amphetamines, and/or cannabis, but 
dependence on alcohol or benzodiazepines was exclusionary. OD was part of a 
buprenorphine treatment program focusing on smoking cessation and they were studied 
before smoking cessation. For group comparisons of metabolite concentrations specifically 
in the ACC, DLPFC, and POC and when correlated with neuropsychological variables, there 
were data from thirty-five cigarette smoking ALC recruited from local treatment programs 
of the VA and Kaiser Permanente and 28 cigarette smoking CON recruited from the 
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community. The ALC group met DSM-IV criteria for alcohol dependence and was abstinent 
from alcohol (not tobacco) for 21 ± 11 days at time of study. For group comparisons of 
metabolite concentrations in the OFC and when correlated with neuropsychological 
variables (the OFC VOI only), smokers and non-smokers were included in the ALC and 
CON groups: 21 ALC (9 nonsmokers, 12 smokers) and 19 CON (14 non-smokers, 5 
smokers) due to a lack of sufficient data in smokers. All participants were studied with 
structural MRI, 1H MRS, and neuropsychological testing, all were fluent in English and 
they were allowed to smoke ad libitum before assessment and during breaks. Table 1 
contains demographics, tobacco and alcohol use variables, mood measures, and laboratory 
variables for the three groups.
Further exclusion criteria for ALC and CON are described elsewhere [30]. In brief, ALC and 
CON participants were excluded for neurological disorders (e.g. seizures, neurodegenerative 
disorder, traumatic brain injury with loss of consciousness >5 min), psychiatric disorders 
(e.g. history of schizophrenia spectrum, bipolar and panic disorders, posttraumatic stress 
disorder), and medical and vascular risk factors (e.g. endocrine diseases, chronic obstructive 
pulmonary disease, type-1 diabetes, myocardial infarction, cerebrovascular accident, 
migraine headaches), known to affect neurobiology or cognition as well as for MRI 
contraindications. In OD and ALC, hepatitis C, type-2 diabetes, hypertension, unipolar 
mood disorder, or generalized anxiety disorders were not exclusionary due to their high 
prevalence in addiction [31–35]. Six OD, 4 ALC and 1 CON had hepatitis C (by self-report 
and medical chart review), while 4 OD and 13 ALC had medically-controlled hypertension.
All OD were on buprenorphine maintenance therapy averaging 15 ± 9 mg/day. Table 2 
depicts their recent and lifetime substance use histories. Overall, OD as a group were all 
cigarette smokers (by design) and had comorbid stimulant and marijuana use over lifetime, 
which they reduced during the year before study. Only a few OD individuals had drug use 
within the last 30 days: 3 used opiates and/or cocaine but only 1 used opiates for 20 days, 1 
other OD used amphetamines daily, and about one-third of the sample used marijuana. The 
majority of OD individuals were moderate alcohol drinkers over their lifetime, but they 
reduced their alcohol consumption during the last year before study; only 3 had consumed 
alcohol on more than 10 days within the last 30 days. The ALC group for the ACC, DLPFC, 
and POC VOI analyses were cigarette smokers abstinent from alcohol for about 3 weeks and 
used other drugs occasionally (5 ALC used marijuana and 1 ALC used cocaine within the 
last 30 days). Thus, the ALC group for the majority of the analyses (3 of 4 VOIs) and the 
entire OD group were cigarette-smoking treatment seekers, abstinent from their main drug 
of abuse for several weeks and they had similarly low levels of drug use within the last 
month before study.
Clinical, neurocognitive and behavioural assessment
OD and ALC completed the Structured Clinical Interview for DSM-IV Axis I disorders 
Patient Edition, v2.0 [36], CON were administered the corresponding screening module. The 
clinical and neurocognitive assessments of ALC and CON are detailed elsewhere [30]. In all 
groups, alcohol consumption was estimated with the lifetime drinking history interview 
[37,38], nicotine dependence was assessed with the Fagerstrom Tolerance Test for Nicotine 
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Dependence [39], and lifetime substance use history (other than alcohol) was assessed with 
an in-house questionnaire [40]. All participants completed the Beck Depression Inventory 
(BDI; [41]) and the State-Trait Anxiety Inventory (STAI; [42]).
A neurocognitive battery assessed the major domains affected by opioid and alcohol use 
disorders and Z-scores were calculated based on corresponding normative data. Cognitive 
domains were formed from specific neurocognitive tasks (see [30] for details and Table 3). 
The cognitive domain scores in ALC and CON were calculated according to the shortened 
neurocognitive battery of tests administered to the OD group and therefore, the constituent 
measures for cognitive domains in this study are different from our previous publications. 
All participants completed self-regulation measures, which included the BIS to assess self-
reported impulsivity, the Balloon Analogue Risk Task (BART; [43]) to assess risk taking, 
and the Iowa Gambling Task (IGT; [44]) to assess decision making. Laboratory tests within 
2–3 days of the MR scan evaluated the nutritional status and alcohol-related or other 
hepatocellular injury in OD and ALC. See Table 1 for laboratory variables, cognitive domain 
and self-regulation measures for the three groups.
Magnetic resonance methods
MR data were acquired on a 4 T Bruker MedSpec system with a Siemens Trio console 
(Siemens, Erlangen, Germany) using an 8- channel transmits-receive head coil. 3D sagittal 
T-1-weighted and 2D axial T2-weighted images were acquired using Magnetization 
Prepared Rapid Gradient imaging (TR/TE/TI=2300/3/950 ms, 7º flip angle, 1 × 1 × 1 mm3 
resolution) and turbo spin-echo (TR/TE=8400/70 ms, 150º flip angle, 0.9 × 0.9 × 3 mm3 
resolution) sequences, respectively. NAA, creatine+phosphocreatine (Cr), choline containing 
metabolites (Cho), myo-Inositol (mI) and Glu signals in MRS volumes-of-interest (VOIs) 
were acquired with a Stimulated Echo Acquisition Mode (STEAM) sequence (TR/TE/
TM=2000/12/10 ms, 90º flip angle, 2000 Hz spectral bandwidth, 2.5 min) ([45]) and placed 
over the ACC (35 × 25 × 20 mm3), right DLPFC (20 × 40 × 20 mm3), right OFC (40 × 20 × 
10 mm3) at the base of the inferior prefrontal cortex, and medial parieto-occipital region 
(POC; 40 × 20 × 20 mm3) to maximize the corresponding cortical gray matter (GM) content. 
See Figure 1 for VOI placements and example MR spectra. γ-aminobutyric acid (GABA) 
signals from ACC, DLPFC and POC were acquired from the exact same VOIs with a 
modified J-editing sequence (MEGA PRESS: TR/TE=2000/71, 90º flip angle, 2000 Hz 
spectral bandwidth, 12.5 min) [46]). STEAM and GABA spectra were not always acquired 
from all VOIs in all participants and the numbers of VOI-specific spectra analysed are 
shown in Table 4. The corresponding structural MR images were segmented into GM, white 
matter (WM), and cerebrospinal fluid (CSF; [47]) to estimate tissue fraction and CSF 
contributions to each VOI for calculation of metabolite concentrations in institutional units 
(i.u). Quantitated metabolite concentrations were corrected for CSF contribution and scaled 
to the water level from the corresponding VOI (Table 4).
For full methods details see [48]. Twelve percent of CON and 47% of ALC participants of 
the current study were included in our previous reports on metabolite concentrations in 
individuals with alcohol and poly-substance dependence [48,49].
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Statistical analyses
Univariate analyses of covariance (ANCOVA) tested for group differences on demographic 
and clinical variables. All statistical analyses were performed with SPSS version 22. 
Separate ANCOVAs were performed for the four VOIs and each metabolite, followed by 
planned pairwise comparisons to test for group differences in metabolite concentrations 
between OD, ALC and CON. Given the participants’ wide age range (23–60 years) and as 
age correlates with metabolite concentrations (e.g., [50]), age was used as a covariate in 
group comparisons. As GM, WM, and CSF contributions to the VOIs affect brain metabolite 
levels [51] and as tissue content in ACC and OFC VOIs differed between groups (see Table 
4), we included these variables as predictors in the ANCOVAs.
Each a priori hypothesis was tested with an alpha level of 0.05. In pairwise group 
comparisons of metabolite levels without a specific a priori hypothesis, we used corrected 
alpha levels to account for the multiplicity of metabolites in each VOI via a modified 
Bonferroni procedure [52], which yielded adjusted alpha levels for each VOI separately by 
using the number of metabolites under investigation and their average inter-correlation 
coefficients (ACC: r=0.26; DLPFC: r=0.42; OFC: r=0.62; POC: r=0.44). The adjusted alpha 
levels for statistical significance were p=0.018 for ACC, 0.022 for DLPFC, 0.038 for OFC, 
and 0.020 for POC. OFC spectra often did not have a well-defined mI resonance (overlap 
with residual water) and therefore, OFC mI was not analysed. Effect sizes were calculated 
via Cohen’s d [53]. Correlations between outcome measures were corrected for age (i.e., 
partial correlations), except for correlations with cognitive domains (based on age-adjusted 
normative data), and reported as Pearson coefficients.
Results
Participant characterization
Age and years of education did not differ between OD and CON (Table 1). ALC were 
equivalent on age to OD and CON, but had fewer years of education. OD had lower 
hemoglobin and hematocrit than both CON and ALC. There were no significant differences 
in blood tests of liver function (γ-GTP, Albumin, Aspartate Aminotransferase, Alanine 
Aminotransferase and Alkaline Phosphatase) in individuals with and without Hepatitis C 
within the ALC group and also within the OD group. In addition, none of the individuals 
with Hepatitis C were taking medications at the time of study for Hepatitis C. Furthermore, 
the individuals taking hypertension medication did have controlled blood pressure by self-
report but blood pressure levels at time of study were not measured. Nicotine dependence 
scores were higher in OD than ALC; OD and CON also smoked significantly more 
cigarettes per day than ALC, but all groups were equivalent on cigarette smoking duration. 
Gender did not contribute to any group difference or correlation. See Table 1 for drinking 
severity measures in OD, CON and ALC.
Group comparisons of metabolite concentrations
Significant main effects of group were observed for NAA, Cr, and mI in the ACC and for 
NAA, Cr, mI, and Glu in the DLPFC (Table 5). In pairwise comparisons of OD and CON, 
the DLPFC showed the greatest magnitude metabolite concentration differences, with effect 
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sizes up to 1.64. Specifically, NAA, Glu, Cr, and mI were all significantly lower in OD (all 
p<0.01) than CON and ALC. OD also had lower NAA, Cr, and mI concentrations in the 
ACC (all p<0.001), while ACC Glu tended to be lower than in CON (p=0.06). GABA 
concentrations did not differ between OD and CON in any region. In the OFC, metabolite 
concentrations were not different between OD and CON, while Cho tended to be higher in 
OD (p=0.09). The CON group for OFC comparisons comprised both smokers and non-
smokers; in previous MRS research, smoking CON revealed metabolite deficits compared to 
non-smoking CON in DLPFC NAA, Cr, mI and Glu [54]. Here, we found lower OFC Cho 
and Glu in smoking versus non-smoking CON (effect size 1.55). Correspondingly, OFC Glu 
and Cho were significantly higher in OD than smoking CON (effect sizes 0.6–1.4), with no 
group differences for OFC NAA and Cr. In contrast to frontal VOI metabolite 
concentrations, POC NAA, Cr, Cho, mI and Glu concentrations did not differ significantly 
between OD and CON. The 3 week abstinent ALC did not differ significantly from CON in 
DLPFC metabolite concentrations, however, ALC had NAA and Cr reductions in the ACC 
similar to those of OD. In the OFC, ALC (comprised of both smokers and non-smokers) had 
significantly higher Glu and Cho than CON (potentially driven by the smaller proportion of 
smokers among CON).
Associations between metabolite concentrations and cigarette smoking measures
Cigarette smoking measures did not correlate significantly with metabolite concentrations in 
OD, but trends emerged: ACC NAA and Cr tended to correlate negatively with more 
cigarettes/day (both r>−0.39, p<0.08). In sCON, ACC Glu was negatively associated with 
pack-years (r=−0.41, p=0.04, statistical trend), and in sALC, FTND score and cigarettes/day 
was positively related to OFC mI (both r>0.70, both p<0.02).
Associations between regional metabolite concentrations and substance use in OD
Greater substance use in OD related to altered metabolite concentrations, after adjusting for 
age: DLPFC Glu was negatively associated with lifetime duration of opiate (r=−0.62, 
p=0.004) and cocaine use (r=−0.45, p=0.02) (Figure 2), whereas DLPFC NAA did not 
correlate with any substance use measure. ACC GABA correlated negatively with monthly 
opiate use in the previous year and with monthly cocaine use over lifetime (both r>−0.47, 
both p<0.043, trends after multiple comparison correction). In addition, ACC Cr correlated 
negatively with monthly marijuana use in the previous year (r=−0.54, p=0.016) and over 
lifetime (r=−0.47, p=0.03, statistical trend) and positively with amphetamine use in the 
previous month (r=0.49, p=0.03, statistical trend). Finally, POC Cr correlated negatively 
with longer duration of opiate use (r=−0.58, p=0.014) and mI correlated negatively with 
monthly opiate use in the previous year (r=−0.65, p=0.003).
Cognitive domains and self-regulation in OD
OD had better executive functioning scores than (smoking) CON (p=0.01), but did not differ 
on any other cognitive domain, decision making, or risk taking measure (Table 1). Also, OD 
did not differ significantly from abstinent ALC on cognitive domain scores, decision making 
or risk-taking. In OD, working memory related negatively to lifetime years of opiate use (r=
−0.53, p=0.01). OD performed in the average range of functioning across all domains based 
on the domain z-scores derived from normative data.
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Associations of metabolite concentrations with cognition and self-regulation measures
In OD, DLPFC NAA concentration correlated with executive function (r=0.54, p=0.024, 
uncorrected), and NAA and Cho correlated with visuospatial skills and global cognition (all 
r>0.51, all p<0.031, uncorrected). Also in CON, DLPFC NAA correlated with visuospatial 
skills (r=0.47, p=0.01). In OD, ACC Glu correlated with working memory (r=0.50, p=0.02); 
the low NAA and Glu concentrations in DLPFC and ACC did not correlate with any of our 
measures of self-regulation; only OFC Cr was negatively related to non-planning impulsivity 
(r=−0.65, p=0.021).
Discussion
This study compared cortical metabolite concentrations, neurocognition, and self-regulation 
between cigarette-smoking opiate dependent individuals on buprenorphine maintenance 
therapy, treatment-seeking alcohol dependent smokers, and smoking controls. OD had 
significant metabolite alterations in markers of neuronal integrity (NAA), cell membrane 
turnover/synthesis (Cho), glutamate concentration (Glu), cellular bioenergetics (Cr), and 
astrocyte integrity (mI) in frontal lobe regions implicated in the development and 
maintenance of addictive disorders. OD had lower NAA, Glu, Cr and mI concentrations than 
CON in the DLPFC and lower NAA, Cr and mI in the ACC. The metabolite concentration 
deficits in OD were most pronounced in the DLPFC, were associated with various substance 
use measures, and correlated with worse performance on measures of global cognition, 
executive and visuospatial functioning. However, OD and CON were equivalent in regional 
GABA concentrations, most cognitive domains, and self-regulation measures. Relative to 3 
week abstinent ALC, OD had significantly lower NAA, Cr, Cho and mI concentrations in 
the DLPFC, with NAA and Cho deficits having cognitive ramifications.
Consistent with most previous reports [11–14], we found metabolite deficits in the ACC of 
OD. In addition, OD had similar deficits in NAA, Cr, and Glu concentrations in the DLPFC. 
This suggests reduced neuronal and astrocyte viability and cellular bioenergetics in both the 
ACC and DLPFC, with additional glutamatergic injury in the DLPFC. ACC Glu and also 
DLPFC NAA and Cho metabolite abnormalities related to poorer cognitive function, which, 
however, did not differ significantly from CON. Of note, GABA concentrations in ACC and 
DLPFC of OD were equivalent to those in smoking CON, similar to findings in 3-week 
abstinent ALC versus smoking CON (this study) and 1 week abstinent ALC vs. mostly non-
smoking CON [48]. However, ACC GABA reductions were reported in abstinent individuals 
with cocaine- [55] and polysubstance-dependence [49]. The POC and occipital region have 
been used as control regions in MRS studies as they are typically not altered in addiction 
[56,57]. This appears to be true also for OD, who showed the most pronounced metabolite 
deficits in anterior frontal brain regions.
We also assessed the OFC region previously not investigated in OD. The lateral OFC 
subserves motivation, drive, reward valuation, and aspects of social executive skills, is 
affected in opiate dependence [58] and other drug abuse [59], and the OFC has altered brain 
activity in decision making task-based fMRI studies of individuals with substance use 
disorders [60]. OFC metabolite concentrations did not differ between OD and CON, the 
latter including mostly non-smokers. However, and in contrast to DLPFC and ACC findings, 
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OD showed elevated Glu and Cho concentrations in the OFC when compared to a subset of 
CON, the small group of smoking CON. Although the small group size warrants caution 
when interpreting results, our finding of lower OFC Cho concentration in smoking vs. non-
smoking CON is consistent with lower Cho measured in frontal, midbrain and vermis 
regions of smoking vs. non-smoking controls [61].
In OD, lower DLPFC Glu and strong trends for lower ACC GABA correlated with greater 
severity and duration of opiate use. These findings are congruent with other neuroimaging 
studies that reported lower DLPFC GM density [9,18] and poorer functional connectivity 
between DLPFC and parietal regions associated with greater duration of opiate use [9]. ACC 
Glu and NAA were not related to opiate use, consistent with previous reports [11]. However, 
greater cocaine and marijuana misuse in our OD group was associated with significantly 
lower metabolite concentrations, commensurate with findings in other substance using/
dependent populations [62–64].
Metabolite concentrations in the DLPFC and ACC of OD related to executive function, 
visuospatial skills, global cognition and working memory, but not to self-regulation 
measures. Previous 1H MRS studies in opiate dependence did not report on such 
relationships, but studies in marijuana-dependent and recreational ecstasy users reported 
relationships between altered frontal metabolite levels and impaired cognition or higher 
impulsivity [56,65,66]. Although previous research in opiate addicts reported 
neuropsychological deficits [24,25], our OD group performed in the average range across 
various cognitive domains and self-regulation measures. There is some evidence that 
buprenorphine maintenance is associated with better cognition compared to other 
maintenance drugs [67–70], and buprenorphine has been shown to improve brain perfusion 
in cocaine dependence [71,72]; correspondingly, buprenorphine may have had an effect on 
cognitive performance in OD in this study. Future studies on the effects of buprenorphine on 
brain function and cognition in OD may be useful to inform effective treatment.
Our study showed that OD on maintenance therapy had greater anterior frontal brain 
metabolite abnormalities than 3 week abstinent ALC, and we found previously that even 1 
week abstinent ALC did not show metabolite abnormalities in the DLPFC [48]. The greater 
DLPFC metabolite abnormalities in OD may relate to the greater relapse rate in opiate than 
alcohol dependence [73], which may require differently tailored approaches for treatment of 
OD and ALC. Metabolite deficits in the DLPFC of OD are more reminiscent of 1H MRS 
results in poly-substance users [49,64], recreational cannabis users [62], and 
methamphetamine dependent individuals [63]. The DLPFC is critically involved in executive 
functions, such as working memory, cognitive flexibility, planning, inhibition, and abstract 
reasoning. As such, DLPFC brain metabolite abnormalities, in addition to those in ACC, 
may be promising targets to monitor the efficacy of cognitive behaviour therapy in OD 
treatment, especially as they correlate with cognition and substance use behaviour.
This study has limitations. Drug use histories were based on self-report and gender effects 
across groups could not be assessed due to the small number of females (21%). Menstrual 
cycle appears to affect brain GABA levels [74], but data on the time since last menstrual 
cycle was not collected. However, excluding the female participants from statistical analyses 
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did not alter the finding of no significant GABA differences between groups. The number of 
analysed spectra for some comparisons was relatively small, especially those involving 
smoking CON with OFC and POC VOIs; therefore, these analyses need to be considered 
hypothesis generating rather than definitive. Further, differences to previous metabolite and 
neuropsychological research in OD may relate to differences in comorbid tobacco, alcohol, 
marijuana and stimulant abuse as pointed out previously [28]. Of note in this context is the 
relatively low lifetime and current alcohol use in our OD sample. An additional limitation is 
that the duration of buprenorphine maintenance therapy was not assessed, although OD had 
to be on therapy for at least 3 months. Furthermore, the results may not be generalizable to 
OD who are not on buprenorphine therapy. Finally, we cannot rule out the possible 
contributions of premorbid, developmental, and dietary/nutritional factors to the 
neurobiological group effects reported.
Conclusion
Our findings of regional metabolite concentration abnormalities in the absence of 
neuropsychological deficits in OD are of clinical significance. They extend previous reports 
of ACC metabolite abnormalities in OD to DLPFC and OFC, all important components of 
brain circuitry relevant to relapse risk, and they include comparisons with smoking CON. 
While the findings are largely consistent with the broader literature on prefrontal brain 
deficits in substance users, they also expose differences of the frontal metabolite profile 
between OD and ALC, revealing metabolic abnormalities in OD more similar to those of 
polysubstance, cannabis and methamphetamine users and related to cognitive performance, 
opiate, and comorbid substance use. In efforts to facilitate endogenous neuroplasticity, these 
metabolite abnormalities and comorbid substance use should be explored as important 
targets in the treatment of opiate dependence including heroin addiction. From a 
methodological point-of-view and because MRS measures are related to cognition, 
quantitative 1H MRS may be useful for monitoring both pharmacological and cognitive 
behavioural therapy intended to facilitate abstinence in OD.
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Figure 1. 
OFC compared to ACC and DLPFC VOI STEAM spectra shown as fitted after DC-
correction and apodization. For all VOIs, the experimental spectra are represented in white 
and the fitted baseline is displayed in purple. The green line overlying the white line in the 
bottom spectra for each VOI represent the convergence of the summed spectral fits for each 
metabolite resonance.
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Figure 2. 
In OD, the associations of DLPFC Glu concentration (in institutional units, i.u.) with opiate 
and cocaine use.
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Table 2
Substance use histories of the OD group.
Substance % Duration in yrs Lifetime g/mo Previous yr g/mo
Opiates 100 11 ± 7 (2–22) 16 ± 14 (0.04–43) 6 ± 13 (0.5–44; n=7)
Tobacco 100 23 ± 11 (7–45) 554 ± 242 (180–1200)^ not available
Alcohol* 90 23 ±12 (6–44) 57 ± 52 (1–94) 47 ± 101 (1–330)
Cocaine 71 5 ± 7 (1–25) 24 ± 52 (2–240) 3 ± 8 (0.25–32)
Methadone 62 2 ± 3 (1–10) not available not available
Marijuana 62 18 ± 13 (3–41) 17 ± 24 (2–90) 8 ± 23 (2–90)
Amphetamines 38 2 ± 3 (3–10) 4 ± 9 (0.5–38) 0.2 ± 1 (0.5–4; n=2)
Mean ± standard deviation; range in parentheses,
^Cigarettes/mo,
*Quantities in alcoholic drinks per month; 1 drink defined as containing 13.6 g of ethanol.
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Table 3
Cognitive domains formed and constituent measures.
Cognitive Domain Constituent Measures
Executive functions
• Short Categories Test [75]
• Stroop Test, color-word subtest [76]
• Trail Making Test B [77]
• Wisconsin Card Sorting Test-64 (WCST-64): Computer Version 2-Research Edition non-perseverative errors, 
perseverative errors, perseverative responses [78]
Visuospatial skills • Wechsler Adult Intelligence Scale 3rd Edition (WAIS-III) Block Design [79]
Processing speed
• WAIS-III Digit Symbol [79]
• WAIS-III Symbol Search [79]
• Stroop, colour-word subtests [76]
• Trail Making Test A [77]
Working memory
• WAIS-III Arithmetic [79]
• WAIS-III Digit Span [79]
Global cognition • The arithmetic average of z-scores for all of the individual cognitive domains
Cognitive efficiency
• The arithmetic average z-scores for tests that were timed, or where the time to complete the task influenced the score 
obtained
• Stroop Test, colour-word subtest [76]
• Trail Making Test A and B [77]
• WAIS-III Arithmetic, Block Design, Digit Symbol, Symbol Search [79]
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